Labetalol S.A.L.F. (Labetalol Hydrochloride)

Labetalol works by simultaneously blocking beta‑adrenergic receptors (β1 and β2) and alpha‑1 receptors. This dual antagonism lowers heart rate, reduces myocardial contractility, and dilates peripheral blood vessels, resulting in decreased systemic vascular resistance and blood pressure.

The specific dose of Labetalol S.A.L.F. is determined by the prescribing clinician based on the patient’s condition, severity of hypertension, and response to therapy. Healthcare professionals adjust the infusion rate or bolus amount to achieve target blood pressure goals.

Safety data for labetalol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with pure beta‑blockers, labetalol adds alpha‑1 blockade, offering better control of peripheral vascular resistance. Unlike rapid‑acting vasodilators such as nitroprusside, labetalol provides a more gradual blood‑pressure reduction and can be used when both heart‑rate control and vasodilation are desired.

Labetalol S.A.L.F. should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The product is given intravenously, either as a slow bolus injection or as a continuous infusion, according to the clinician’s prescription. Administration is performed under continuous monitoring of blood pressure and heart rate.

The most serious risks include severe hypotension, marked bradycardia, heart block, bronchospasm in asthmatic patients, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential.

Labetalol is contraindicated in patients with known hypersensitivity to labetalol, severe bradycardia, second‑ or third‑degree heart block without a pacemaker, overt heart failure, and in those with uncontrolled asthma or severe chronic obstructive pulmonary disease.